medigraphic.com
ISSN 0016-3813 (Print)

2007, Number 5

Next >>

Gac Med Mex 2007; 143 (5)

Colaboraciones exitosas entre tres instituciones mexicanas en el estudio de las dislipidemias, la obesidad y la diabetes

Aguilar-Salinas CA, Canizales-Quinteros S, Rojas-Martínez R, García-García E, Olaiz-Fernández G, Gómez-Péreza FJ, Tusié-Luna MT

Language: Spanish
References: 52
Page: 355-364
PDF size: 148.84 Kb.


ABSTRACT

Objective: To describe the contributions of three Mexican institutions (Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán”, Universidad Nacional Autónoma de México and the Centro de Encuestas Nacionales de Salud of the Instituto Nacional de Salud Pública) in the study of chronic degenerative disorders.
Results: The most relevant group contributions include: the identification of a risk allele for metabolic syndrome and diabetes, specific for the Mexican population (the R230C variant of the ABCA1 transporter); the design and validation of a population-based definition of metabolic syndrome which is useful to predict the risk of incident diabetes; the description of the molecular epidemiology of familial hypercholesterolemia in Mexico and the identification of several loci associated with familial combined hyperlipidemia. In addition, members of these institutions have participated in the description of the epidemiology of diabetes, metabolic syndrome and lipid abnormalities.
Conclusions: The complementary approach of these research groups has facilitated successful collaborations. Our results will be useful for the future development of diagnostic tests and preventive programs.


REFERENCES

  1. Aguilar-Salinas CA, Gómez-Pérez FJ. La declaración de Acapulco. Rev Invest Clin 2006;58:71-77.

  2. Lindstrõm J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson J, Hemio K, Hamalainen H, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention:follow-up of the Finnish Diabetes Prevention Study. Lancet 2006;368:1673-1679.

  3. Strong K, Mathers C, Leeder S, Beaglehole R. Preventing chronic diseases: how many lives can we save. Lancet 2005;366:1578-1582.

  4. Epping-Jordan, Galea G, Tukuitonga C, Beaglehole R. Preventing chronic diseases: taking stepwise action. Lancet 2005;366:1667-1671.

  5. Soriguer F, Morcillo S, Cardona F, Rojo-Martínez G, de la Cruz-Almaraz M, Ruiz de Adana M de L, et al. Pro12Ala polymorphism of the PPARG2 gene is associated with type 2 diabetes mellitus and peripheral insulin sensitivity in a population with a high intake of oleic acid. J Nutr 2006;136:2325-2330.

  6. Stefanski A, Majkowska L, Ciechanowicz A, Frankow M, Safranow K, Parczewski M, et al. Lack of association between the Pro12Ala polymorphism in PPAR-gamma2 gene and body weight changes, insulin resistance and chronic diabetic complications in obese patients with type 2 diabetes. Arch Med Res 2006;37:736-743.

  7. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, et al. A genomewide association study identifies novel risk loci for type 2 diabetes. Nature 2007;445:881-885.

  8. Aguilar-Salinas CA, Gómez-Pérez FJ, Lerman I, Pérez O, Posadas C. Diagnóstico y tratamiento de las dislipidemias. Postura de la Sociedad Mexicana de Nutrición y Endocrinología. Rev Endocrinol Nutr 2004;12:7-41.

  9. Aguilar-Salinas CA, Olaiz G, Valles V, Ríos JM, Gómez-Pérez FJ, Rull JA, et al. High prevalence of low HDL cholesterol concentrations and mixed hyperlipidemia in a Mexican nation wide survey. J Lipid Res 2001;42:1298-1307.

  10. Aguilar-Salinas CA, Rojas R, Gómez-Pérez FJ, Valles V, Franco A, Olaiz G, et al. Características de los casos con dislipidemias mixtas en un estudio de población: resultados de la Encuesta Nacional de Enfermedad Crónicas. Salud Publica Mex 2002;44:546-553.

  11. Rojas R, Aguilar-Salinas CA, Gómez-Pérez FJ, Valles V, Franco A, Olaiz G, et al. Applicability of the National Cholesterol Education Program III (NCEP-III) Guidelines for treatment of dyslipidemia in a non-Caucasian population: a Mexican Nation-Wide Survey. Rev Invest Clin 2005;57:28-37.

  12. Valles V, Aguilar-Salinas CA, Gómez-Pérez FJ, Rojas R, Franco A, Olaiz G, et al. Apolipoprotein B and AI distribution in the Mexican urban adults: Results of a Nation-Wide Survey. Metabolism 2002;51:560-568.

  13. Aguilar-Salinas CA, Rojas R, Gómez-Pérez FJ, García E, Valles V, Ríos- Torres JM, et al. Early onset type 2 diabetes in a Mexican, population-based, nation-wide survey. Am J Med 2002;113:569-574.

  14. Aguilar-Salinas CA, Mehta R, Rojas R, Gómez-Pérez FJ, Olaiz G, Rull JA. Management of the metabolic syndrome as a strategy for preventing the macrovascular complications of type 2 diabetes: controversial issues. Curr Diabetes Rev 2005:1:145-158.

  15. Rull JA, Aguilar-Salinas CA, Rojas R, Ríos-Torres JM, Gómez-Pérez FJ, Olaiz G. Epidemiology of type 2 diabetes in México. Arch Med Res 2005;36:188-196.

  16. Aguilar-Salinas CA, Rojas R, Ríos-Torres JM, Gómez-Pérez FJ, Olaiz G, Rull JA. The metabolic syndrome: a concept in evolution. Arch Med Res 2005:36:223-231.

  17. Aguilar-Salinas CA, Rojas R, Gómez-Pérez FJ, Valles V, Ríos-Torres JM, Franco A, et al. High prevalence of the metabolic syndrome in México. Arch Med Res 2004;35:76-81.

  18. Villarreal-Molina MT, Aguilar-Salinas CA, Rodríguez-Cruz M, Riaño D, Villalobos- Comparán M, Flores-Dorantes MT, et al. The ABCA1 R230C variant affects HDL cholesterol levels and body mass index in the Mexican population: association with obesity and obesity-related co-morbidities. Diabetes 2007:56:1881-1887.

  19. Robles L, Huerta A, Ordóñez ML, Canizales S, Díaz A, Gutiérrez R, et al. Mutational and genetic linkage analyses of autosomal dominant hypercholesterolemia in Mexico: evidence for further genetic heterogeneity. Arch Med Res 2006;37:102-108.

  20. Aguilar-Salinas CA, Rojas R, González-Villalpando C, Gómez-Pérez FJ, Mehta R, Olaiz G, et al. Design and validation of a population-based definition of the metabolic syndrome. Diabetes Care 2006:2420-2426.

  21. Aguilar Salinas CA, Huertas A, Tusié MT, Gómez-Pérez FJ, Rull JA Hiperlipidemia familiar combinada. Rev Endocrinol Nutr 2002;10:58-62.

  22. González-Villalpando C, Stern MP, Valdez R, Mitchell B, Haffner S. Niveles de lípidos sanguíneos y riesgo aterogénico en población urbana abierta. Rev Invest Clin 1993;45:127-132.

  23. González-Villalpando C, Stern MP, Arredondo PB, Martínez DS, Haffner SM. Undiagnosed hypercholesterolemia: a serious health challenge. The Mexico City Diabetes Study. Arch Med Res 1996;27:19-23.

  24. Robles-Osorio L, Ordóñez ML, Aguilar-Salinas CA, Aurón-Gómez M, Tusié- Luna MT, Gómez-Pérez FJ, et al. Familial hypercholesterolemia due to a ligand-defective apolipoprotein B-100. First case-report in a Mexican family. Arch Med Res 2003;34:70-75.

  25. Canizales-Quinteros S, Aguilar-Salinas CA, Reyes-Rodríguez E, Riba L, Rodríguez-Torres M, Ramírez-Jiménez S, et al. Locus on chromosome 6p linked to elevated HDL-C serum levels, and to protection against premature atherosclerosis in a kindred with familial hypercholesterolemia. Circulation Res 2003:92:569-576.

  26. Canizales-Quinteros S, Aguilar-Salinas CA, Huertas-Vázquez A, Ordóñez-Sánchez ML, Rodríguez-Torres M, Venturas-Gallegos JL, et al. A novel ARH splice site mutation in a Mexican kindred with autosomal recessive hypercholesterolemia and evidence of possible interaction between the 1p35 and 15q25-26 loci in the expression of the disease. Human Genetics 2005;116:114-120.

  27. Aguilar-Salinas CA, Zamora M, Gómez- Díaz RA, Mehta R, Gómez-Pérez FJ, Rull JA. Familial combined hyperlipidemia: controversial aspects of its diagnosis and pathogenesis. Sem Vasc Med 2004:4:203-209.

  28. Del Rincón-Jarero JP, Aguilar-Salinas CA, Guillén-Pineda LE, Gómez- Pérez FJ, Rull JA. Lack of agreement between the plasma lipid based criteria and the apoprotein B for the diagnosis of familial combined hyperlipidemia (FCHL) in members of FCHL kindreds. Metabolism 2002;51:218-224.

  29. Aguilar-Salinas CA, Barrett HP, Pulai J, Zhu X, Schonfeld G. Description of a kindred with familial combined hyperlipidemia with unusual kinetic abnormalities of the apolipoprotein B containing lipoproteins. Effects of pravastatin therapy. Arterios Thromb Vasc Biol 1997;17:72-82.

  30. Huertas-Vázquez A, del Rincón-Jarero JP, Canizales-Quinteros S, Vega- Hernández G, Riba L, Ramírez-Jiménez S, et al.. Replication of linkage of familial combined hyperlipidemia to chromosome 1q21-q23 in Mexican families. Ann Human Genet 2004;68:419-427.

  31. Huertas-Vázquez A, Aguilar Salinas C, Lusis A, Cantor R, Canizales A, Lee J, et al. Familial combined hyperlipidemia in Mexicans. Association with upstream transcription factor 1 and linkage on chromosome 16q24.1. Arterios Thromb Vasc Biol 2005;25:1985-1991.

  32. Weissglas D, Huertas-Vázquez A, Canizalez S, Suviolahti E, Lee J, Aguilar- Salinas CA, et al. Common hepatic nuclear factor 4 alpha variants are associated with high serum lipid levels and the metabolic syndrome. Diabetes 2006;55:1970-1977.

  33. Aguilar-Salinas CA, Díaz- Polanco A, Quintana E, Macías M, Arellano A, Ramírez E, et al. Genetic factors play an important role in the pathogenesis of hyperlipidemia post-transplantation. Am J Kidney Dis 2002;40:169-177.

  34. Tamez R, Aguilar-Salinas CA, Gómez-Pérez FJ. Prevalencia de las dislipidemias primarias en pacientes con diabetes sobrevivientes de un evento coronario. Rev Endocrinol Nutr 2004;12:42-45.

  35. Mehta R, Loredo B, Sañudo ME, Hernández-Jiménez S, Rodríguez-Carranza SI, Gómez-Pérez FJ, et al Epidemiología de las anormalidades metabólicas en pacientes con infección por VIH. Rev Invest Clin 2004:56:209-221.

  36. Lara-Esqueda A, Aguilar-Salinas CA, Velázquez O, Gómez-Pérez FJ, Rosas M, Mehta R, et al. The body mass index is a less sensitive tool for detecting cases with obesity related co-morbidities in short stature subjects. Int J Obes Relat Metab Disord 2004;28:1443-1450.

  37. Probst MC, Thumann H, Aslanidis C, Langmann T, Buechler C, Patsch W,et al. Screening for functional sequence variations and mutations in ABCA1. Atherosclerosis 2004;175:269-279.

  38. Wang J, Burnett JR, Near S, Young K, Zinman B, Hanley AJG, et al. Common and rare ABCA1 variants affecting plasma HDL cholesterol. Arterios Thromb Vasc Biol 2000;20:1983-1989.

  39. Canizales-Quinteros S, Aguilar-Salinas CA, Ortiz-López G, Rodríguez- Cruz M, Villarreal-Molina MT, Coral-Vázquez R, et al. Association of PPAR gamma 2 Pro12Ala variant with larger body mass index in Mestizo and Amerindian populations of Mexico. Human Biol 2007;78:111-117.

  40. Olaiz G, Rojas R, Barquera S, Shamah T, Aguilar-Salinas C, Cravioto P, et al. Encuesta Nacional de Salud 2000. Tomo 2. La salud de los adultos. Instituto Nacional de Salud Pública. Cuernavaca, Morelos, México. 2003.

  41. Aguilar-Salinas CA, Velásquez-Monroy O, Gómez-Pérez FJ, González- Chávez A, Lara-Esqueda A, Molina-Cuevas V, et al. Characteristics of the patients with type 2 diabetes in México: results from a large population-based, nation-wide survey. Diabetes Care 2003:26:2021-2026.

  42. González-Villalpando C, Stern MP, Villalpando E, Hazuda H, Haffner S, Lisci E. Prevalencia de diabetes e intolerancia a la glucosa en una población urbana de nivel económico bajo. Rev Invest Clin 1992;44:321-328.

  43. Stern MP, González-Villalpando C, Mitchell B, Villalpando E, Haffner S, Hazuda H. Genetic and environmental determinants of type 2 diabetes in Mexico City and San Antonio. Diabetes 1992;41:484-492.

  44. Gómez-Pérez FJ, Aguilar-Salinas CA, López-Alvarenga JC, Guillén LE, Wong B, Rull-Rodrigo JA. Lack of agreement between the World Health Organization category of impaired glucose tolerance and the American Diabetes Association category of impaired fasting glucose Diabetes Care 1998;21:1886-1888.

  45. Gómez-Pérez FJ, Aguilar-Salinas CA, Vázquez-Chávez C, Fanghänel- Salmón G, Gallegos-Martínez J, Gómez-Díaz R, et al. Further insight on the hypoglycemic and non-hypoglycemic effects of troglitazone 400 or 600 mg/day: Effects on the VLDL and HDL lipoprotein particle distribution. Metabolism 2002;51:44-51.

  46. Gómez-Pérez FJ, Fanghänel-Salmon G, Barbosa J, Montes-Villarreal J, Berry RA, Warsi G, et al. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Metab Res Rev 2002;18:127-134.

  47. Gómez-Pérez FJ, Rull JA, Díes H, Rodríguez-Rivera JG, González-Barranco J, Lozano-Castaneda O. Nortriptyline and fluphenazine in the symptomatic treatment of diabetic neuropathy. A double-blind cross-over study. Pain 1985; 23:395-400.

  48. Canizales-Quinteros S, Huertas-Vázquez A, Riba- Ramírez L, Monroy- Guzmán A, Domínguez-López A, Romero-Hidalgo S, et al. Identifying different susceptibility loci associated with early onset diabetes and cardiovascular disease in Mexican families. Gac Med Mex 2005;141:115-122.

  49. Navalón-García K, Mendoza-Alcántar L, Díaz-Vargas ME, Martínez- Godínez MA, Reyna-Garfias H, Aguilar-Salinas CA, et al. HNF-1alpha G574S is a functional variant with decreased transactivation activity. Diabetes Med 2006;23:1295-1300.

  50. Aguilar-Salinas CA, Reyes-Rodríguez E, Ordóñez-Sánchez ML, Arellano Torres M, Ramírez-Jiménez S, Domínguez-López A, et al. Early-onset type 2 diabetes: metabolic and genetic characterizarion in Mexican population. J Clin Endoc Metab 2001;86:220-226.

  51. Domínguez-López A, Miliar-García A, Segura-Kato YX, Riba L, Esparza- López R, Ramírez-Jiménez S, et al. Mutations in MODY genes are not common cause of early-onset type 2 diabetes in Mexican families. JOP 2005; 10:238-245.

  52. del Bosque-Plata L, Aguilar-Salinas CA, Tusié-Luna MT, Ramírez-Jiménez S, Rodríguez-Torres M, Aurón-Gómez M, et al. Association of the calpain-10 gene with type 2 diabetes mellitus in a Mexican population. Mol Genet Metab 2004;81:122-126.




2020     |     www.medigraphic.com